Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity.

TitlePredicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity.
Publication TypeJournal Article
Year of Publication2015
AuthorsMajumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M, Brijwani N, Pinto DD, Prasath A, Shanthappa BU, Thayakumar A, Surendran R, Babu GK, Shenoy AM, Kuriakose MA, Bergthold G, Horowitz P, Loda M, Beroukhim R, Agarwal S, Sengupta S, Sundaram M, Majumder PK
JournalNat Commun
Volume6
Pagination6169
Date Published2015 Feb 27
ISSN2041-1723
KeywordsAlgorithms, Analysis of Variance, Antineoplastic Agents, Chromatography, Liquid, DNA Mutational Analysis, Extracellular Matrix Proteins, Gene Expression Profiling, Humans, Machine Learning, Microscopy, Electron, Scanning, Precision Medicine, Predictive Value of Tests, Tandem Mass Spectrometry, Tissue Engineering, Tumor Microenvironment
Abstract

Predicting clinical response to anticancer drugs remains a major challenge in cancer treatment. Emerging reports indicate that the tumour microenvironment and heterogeneity can limit the predictive power of current biomarker-guided strategies for chemotherapy. Here we report the engineering of personalized tumour ecosystems that contextually conserve the tumour heterogeneity, and phenocopy the tumour microenvironment using tumour explants maintained in defined tumour grade-matched matrix support and autologous patient serum. The functional response of tumour ecosystems, engineered from 109 patients, to anticancer drugs, together with the corresponding clinical outcomes, is used to train a machine learning algorithm; the learned model is then applied to predict the clinical response in an independent validation group of 55 patients, where we achieve 100% sensitivity in predictions while keeping specificity in a desired high range. The tumour ecosystem and algorithm, together termed the CANScript technology, can emerge as a powerful platform for enabling personalized medicine.

DOI10.1038/ncomms7169
Alternate JournalNat Commun
PubMed ID25721094
PubMed Central IDPMC4351621
Grant ListP50 CA090381 / CA / NCI NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700